AAD Highlights 2016

2016 AAD Annual Meeting content is made available to an international audience through a licensing agreement between Infomedica and the
American Academy of Dermatology and supported by an unrestricted educational grant from

From the Plenary

Dr. Anthony S. Fauci
Director, National Institute of Allergy and Infectious Diseases (NIAID)

Dr. Amy Paller
Northwestern University, Feinberg School of Medicine AAD 2016 Award Winner

Conference Summaries

Welcome to the Highlights from AAD 2016

We are delighted to bring these highlights from the 74th Annual Meeting of the American Academy of Dermatology (AAD), held in Washington, DC, from March 4 to March 8, 2016. Read more

Highlights from
the Plenary Session

A Revolution in the Treatment
of Psoriasis: A Review of New and Emerging Therapies

Hot Topic Update:
Advanced Melanoma

Hot Topic Update:
Atopic Dermatitis

Procedural Dermatology:
Insights from the Late
Breaking Research

CLEAR Study:
Sustained Superiority With
Secukinumab Versus Ustekinumab

Novel Agent Nemolizumab
Reduced Pruritus, Improved Atopic Dermatitis

Novel PDE-4 Inhibitor Safe,
Effective in Mild-to-Moderate Atopic Dermatitis

UNCOVER-2 Analyses Provide
Additional Treatment Insights

IL-17A Inhibition With Ixekizumab Durable in Psoriasis Patients
in UNCOVER-3 Study

Cutaneous Malignancies:
Does Immunotherapy Have a Role?

Cardiovascular Event Reduction
With TNF-Inhibitors in Patients
with Psoriasis

See all...

AAD 2016

HIGHLIGHTS FROM THE 74th ANNUAL MEETING
of the american academy of dermatology
Washington, DC, March 4-8, 2016

In collaboration with

AAD 2016
HIGHLIGHTS FROM 74TH ANNUAL MEETING OF THE
AMERICAN ACADEMY OF DERMATOLOGY

From AAD Presidency

From the Plenary

Conference Summaries

Welcome to the Highlights from AAD 2016

Highlights from
the Plenary Session

A Revolution in the Treatment
of Psoriasis: A Review of New and Emerging Therapies

Hot Topic Update:
Advanced Melanoma

Hot Topic Update:
Atopic Dermatitis

Procedural Dermatology:
Insights from the Late
Breaking Research

CLEAR Study:
Sustained Superiority With
Secukinumab Versus Ustekinumab

Novel Agent Nemolizumab
Reduced Pruritus, Improved Atopic Dermatitis

Novel PDE-4 Inhibitor Safe,
Effective in Mild-to-Moderate Atopic Dermatitis

UNCOVER-2 Analyses Provide
Additional Treatment Insights

IL-17A Inhibition With Ixekizumab Durable in Psoriasis Patients
in UNCOVER-3 Study

Cutaneous Malignancies:
Does Immunotherapy Have a Role?

Cardiovascular Event Reduction
With TNF-Inhibitors in Patients
with Psoriasis

Enter your email to download the AAD 2016 Slide Kit

HELP DESK

AAD 2016

HIGHLIGHTS FROM THE 74th ANNUAL MEETINGof the american academy of dermatologyWashington, DC, March 4-8, 2016

In collaboration with

AAD 2016 HIGHLIGHTS FROM 74TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY

From AAD Presidency

From the Plenary

Conference Summaries

Welcome to the Highlights from AAD 2016

Highlights from the Plenary Session

A Revolution in the Treatment of Psoriasis: A Review of New and Emerging Therapies

Hot Topic Update: Advanced Melanoma

Hot Topic Update: Atopic Dermatitis

Procedural Dermatology: Insights from the Late Breaking Research

CLEAR Study: Sustained Superiority With Secukinumab Versus Ustekinumab

Novel Agent Nemolizumab Reduced Pruritus, Improved Atopic Dermatitis

Novel PDE-4 Inhibitor Safe, Effective in Mild-to-Moderate Atopic Dermatitis

UNCOVER-2 Analyses Provide Additional Treatment Insights

IL-17A Inhibition With Ixekizumab Durable in Psoriasis Patients in UNCOVER-3 Study

Cutaneous Malignancies: Does Immunotherapy Have a Role?

Cardiovascular Event Reduction With TNF-Inhibitors in Patients with Psoriasis

Enter your email to download the AAD 2016 Slide Kit

HELP DESK

HIGHLIGHTS FROM THE 74th ANNUAL MEETING
of the american academy of dermatology
Washington, DC, March 4-8, 2016

AAD 2016
HIGHLIGHTS FROM 74TH ANNUAL MEETING OF THE
AMERICAN ACADEMY OF DERMATOLOGY

Highlights from
the Plenary Session

A Revolution in the Treatment
of Psoriasis: A Review of New and Emerging Therapies

Hot Topic Update:
Advanced Melanoma

Hot Topic Update:
Atopic Dermatitis

Procedural Dermatology:
Insights from the Late
Breaking Research

CLEAR Study:
Sustained Superiority With
Secukinumab Versus Ustekinumab

Novel Agent Nemolizumab
Reduced Pruritus, Improved Atopic Dermatitis

Novel PDE-4 Inhibitor Safe,
Effective in Mild-to-Moderate Atopic Dermatitis

UNCOVER-2 Analyses Provide
Additional Treatment Insights

IL-17A Inhibition With Ixekizumab Durable in Psoriasis Patients
in UNCOVER-3 Study

Cutaneous Malignancies:
Does Immunotherapy Have a Role?

Cardiovascular Event Reduction
With TNF-Inhibitors in Patients
with Psoriasis